Contributions
Abstract: EP1371
Type: ePoster
Abstract Category: Clinical aspects of MS - 7 MS symptoms
Background: Dramatic progress has been made for people with relapse-onset multiple sclerosis(MS). However, for the 15% progressive-onset MS cases, the knowledge is limited, and only ocrelizumab was recently confirmed as an effective therapy. To increase our knowledge and improve disease management for progressive-onset MS, understanding the differences between the two MS onset types is vital.
Objective: To examine differences between progressive-onset MS and relapse-onset MS in relation to disability, disability progression, MS symptoms and quality of life on the basis of patient-reported outcomes.
Method: The Australian Multiple Sclerosis Longitudinal Study (AMSLS) database of 1985 cases was used in this cross-sectional study. Associations between onset-type and outcomes were assessed with negative binomial regression and adjusted for confounders such as age, disease duration, gender, and age of diagnosis.
Results: Seventeen of the nineteen outcomes of progressive-onset MS patients were significantly more severe than relapse-onset MS patients after adjustment for confounders, including disability, progression over the last year, fatigue, sensory symptoms, walking difficulties, pain, balance, sexual dysfunction, bladder problems, bowel problems, spasticity, anxiety, depression and EQ-5D (the adjusted mean ratios ranged from 1.11 to 1.52). Importantly, the difference between the two onset types was most pronounced early in the disease process and reduced with increasing MS duration, with the interaction between onset types and MS duration being significant for disability, progression over the last year, walking difficulties, bladder problems, bowel problems and spasticity.
Conclusions: People with progressive-onset MS were significantly worse off on nearly all patient-reported outcomes compared to relapse-onset MS counterparts. The differences were most pronounced early in the disease course. The findings support the work of the International Progressive MS Alliance and highlight the urgency of identifying early interventions for progressive-onset MS.
Disclosure:
Yan Zhang: nothing to disclose
Ingrid van der Mei: nothing to disclose
Bruce Taylor: nothing to disclose
Abstract: EP1371
Type: ePoster
Abstract Category: Clinical aspects of MS - 7 MS symptoms
Background: Dramatic progress has been made for people with relapse-onset multiple sclerosis(MS). However, for the 15% progressive-onset MS cases, the knowledge is limited, and only ocrelizumab was recently confirmed as an effective therapy. To increase our knowledge and improve disease management for progressive-onset MS, understanding the differences between the two MS onset types is vital.
Objective: To examine differences between progressive-onset MS and relapse-onset MS in relation to disability, disability progression, MS symptoms and quality of life on the basis of patient-reported outcomes.
Method: The Australian Multiple Sclerosis Longitudinal Study (AMSLS) database of 1985 cases was used in this cross-sectional study. Associations between onset-type and outcomes were assessed with negative binomial regression and adjusted for confounders such as age, disease duration, gender, and age of diagnosis.
Results: Seventeen of the nineteen outcomes of progressive-onset MS patients were significantly more severe than relapse-onset MS patients after adjustment for confounders, including disability, progression over the last year, fatigue, sensory symptoms, walking difficulties, pain, balance, sexual dysfunction, bladder problems, bowel problems, spasticity, anxiety, depression and EQ-5D (the adjusted mean ratios ranged from 1.11 to 1.52). Importantly, the difference between the two onset types was most pronounced early in the disease process and reduced with increasing MS duration, with the interaction between onset types and MS duration being significant for disability, progression over the last year, walking difficulties, bladder problems, bowel problems and spasticity.
Conclusions: People with progressive-onset MS were significantly worse off on nearly all patient-reported outcomes compared to relapse-onset MS counterparts. The differences were most pronounced early in the disease course. The findings support the work of the International Progressive MS Alliance and highlight the urgency of identifying early interventions for progressive-onset MS.
Disclosure:
Yan Zhang: nothing to disclose
Ingrid van der Mei: nothing to disclose
Bruce Taylor: nothing to disclose